C-JWVPstem cell-derived secretome, multi-active biologics, regenerative factors
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Develop a treatment candidate for dyskinesia associated with Parkinson's disease.
Licensed treatment candidate; Immunis submitted an IND application to the FDA to initiate a Phase I clinical trial.
IND application submitted to the FDA to initiate a Phase I trial.
Develop a stem cell-derived secretome biologic containing regenerative factors that target age-related immune decline, muscle disease, and metabolic disease.
Clinical-grade stem cell-derived secretome product comprised of multiple regenerative factors affecting multiple signaling pathways; delivered intramuscularly in cited studies and trials.
Immunis describes IMM01-STEM as its investigational product and has multiple IMM01-STEM clinical trial records and an expanded access record.
Preclinical publications report improved aged skeletal muscle mass/function during disuse and recovery, and improved adiposity, liver tissue quality, glucose handling, insulin levels, and muscle quality in obese or weight-loss mouse models.
Address metabolic manifestations of aging and disease, including sarcopenic obesity, adiposity, glucose handling, insulin resistance, and liver steatosis/fibrosis.
Stem cell-derived secretome treatment; studied in obese and weight-loss mouse models and reported as treating first patients for sarcopenic obesity.
First patients for sarcopenic obesity reported as treated.
In mice, secretome treatment increased lean mass and muscle weights during high-fat diet exposure, accelerated fat loss during weight loss, improved glucose handling, fasting insulin and HOMA-IR, and improved liver steatosis and fibrosis.
Treat age-related or disease-related skeletal muscle decline, including muscle atrophy, by improving muscle mass, strength, recovery, and tissue quality.
Stem cell-derived secretome treatment administered intramuscularly; evaluated in aged mouse disuse/recovery models and in a Phase 1/2a clinical trial targeting muscle atrophy.
Phase 1/2a clinical trial targeting muscle atrophy reported as successfully completed.
In aged mice, STEM treatment increased soleus muscle mass, fiber cross-sectional area, and grip strength, reduced atrophy and weakness during hindlimb unloading, and altered macrophage, collagen IV, Pax7, and extracellular matrix remodeling measures.
Assess safety and tolerability of IMM01-STEM in patients with muscle atrophy related to knee osteoarthritis.
Open-label dose-escalation clinical study of IMM01-STEM in participants with knee osteoarthritis-related muscle atrophy.
ClinicalTrials.gov record NCT05211986 describes an open-label dose-escalation study, published 2022-09-13.
Develop a treatment candidate for dyskinesia associated with Parkinson's disease.
Licensed treatment candidate with an Investigational New Drug application submitted to the FDA to initiate a Phase I study, according to the supplied BioSpace record excerpt.
IND application submitted to the FDA to initiate a Phase I study.
Develop a stem cell-derived secretome biologic for age-related diseases, immune dysfunction, muscle decline, and metabolic disease.
Complex multi-active biologic derived from partially differentiated human pluripotent stem cell secretome, delivered as an investigational secretome treatment.
First-in-human use reported and Phase 1/2a clinical trial targeting muscle atrophy reported as successfully completed.
Preclinical studies reported improved aged skeletal muscle mass, fiber cross-sectional area, grip strength, macrophage profiles, fibrosis markers, adiposity, glucose handling, insulin resistance, liver steatosis, and tissue quality in mouse models.